Pfizer Finalizes Purchase of Metsera
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Should l Buy PFE?
Acquisition Details: Pfizer has successfully acquired Metsera for $65.60 per share, totaling an enterprise value of approximately $7.0 billion, with potential additional payments based on clinical milestones.
Impact on Trading: Following the acquisition, Metsera's shares will cease trading on the NASDAQ Global Select Market, and the transaction is expected to be dilutive to Pfizer through 2030.
Strategic Importance: Pfizer views this acquisition as a significant investment in the future of medicine, focusing on high-growth therapeutic areas and enhancing its pipeline.
Leadership Statement: Pfizer's CEO, Albert Bourla, emphasized the goal of combining Metsera's innovative portfolio with Pfizer's infrastructure to accelerate the development of new therapies for patients globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.220
Low
24.00
Averages
28.56
High
35.00
Current: 27.220
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GLP-1 Medications Improve Patient Mood, Study Shows
- Mood Improvement Evidence: According to Dr. Angela Fitch, randomized controlled trials indicate that most patients experience mood improvements when treated with GLP-1 medications, suggesting potential psychological benefits of these drugs.
- Monitoring and Observations: At Knownwell, where Dr. Fitch oversees treatment for over 20,000 patients, she noted that they have not observed the emotional flatness described in media reports, indicating the safety and efficacy of GLP-1 treatments.
- Regulatory Developments: The lack of evidence supporting mental health risks has led regulators to remove suicidality warnings from GLP-1 medication labels, reflecting increased confidence in these drugs.
- Comprehensive Care Recommendations: Dr. Fitch advises that patients should receive comprehensive clinical care when obtaining GLP-1 prescriptions, emphasizing that psychological counseling and behavioral management are crucial for addressing mood shifts beyond medication alone.
See More
QSM Asset Management Initiates Position in Mobileye
- New Investment Position: According to an SEC filing dated April 15, 2026, QSM Asset Management initiated a new position in Mobileye Global Inc. by acquiring 611,003 shares during Q1 2026, with an estimated transaction value of $5.54 million, indicating confidence in the company's potential.
- Value Fluctuation: By the end of the quarter, the value of Mobileye's position was $4.13 million, reflecting price movements during the period and suggesting a cautious market sentiment regarding its future performance.
- Asset Allocation Insight: This new position constituted 2.02% of QSM's total reportable assets, highlighting the strategic diversification within the firm's investment portfolio, even as Mobileye's stock price has declined by 41.1% over the past year.
- Market Outlook Analysis: Despite facing significant market challenges, QSM's acquisition may signal an optimistic outlook for future profitability, particularly as autonomous driving technologies gain increasing importance in the automotive sector.
See More
QSM Asset Management Increases Stake in Mobileye
- Increased Holdings: QSM Asset Management acquired 611,003 shares of Mobileye in Q1 2026, with an estimated trade value of $5.54 million, reflecting confidence in the company's future prospects.
- Quarter-End Valuation: At quarter-end, the value of Mobileye's stake was $4.13 million, representing 2.02% of QSM's reportable assets under management, indicating its significance within the investment portfolio.
- Market Response: Despite Mobileye's stock being down over 80% from its all-time high, analysts project a forward P/E ratio of 30, suggesting the company is poised for profitability and rapid growth.
- Investment Timing: QSM's acquisition is viewed as a bullish signal in the current market climate, particularly as autonomous driving technology gains traction, potentially offering significant returns for investors.
See More
Trump Nominates New CDC Director Amid Turmoil
- Leadership Changes: Trump has nominated Erica Schwartz to serve as the CDC director, concluding a months-long search, with her confirmation pending Senate approval, which could significantly influence the agency's future direction.
- Interim Leadership Issues: Prior to Schwartz's nomination, Jay Bhattacharya served as acting director, but his term expired last month, highlighting instability within the CDC as the Vacancies Act limits interim officials to 210 days.
- Vaccine Policy Controversy: Amid leadership upheaval, declining morale, and significant staff turnover, the CDC faces major changes to U.S. vaccine policy, particularly after a judge blocked efforts to reduce the number of recommended childhood vaccinations, exacerbating public trust issues.
- Declining Public Trust: A February poll from KFF indicates a significant drop in public trust in federal health agencies during Kennedy's tenure as Secretary of Health and Human Services, which may hinder the CDC's effectiveness and implementation of future public health policies.
See More
The Importance of Pfizer's Drug Pipeline
- Vaccine Sales Fluctuation: Pfizer's COVID-19 vaccine revenue surged from $41.6 billion in 2020 to $81.2 billion in 2021, but sales plummeted to around $58 billion in 2023, highlighting the direct impact of changing vaccine demand on the company's financial health.
- Acquisition Strategy: Pfizer's acquisitions of Metsera, which focuses on weight-loss drug candidates in trials, and Seagen, aimed at bolstering its oncology business, reflect a strategic effort to fill future drug pipeline gaps and maintain market competitiveness.
- Stock Performance: Despite significant revenue growth during the COVID-19 vaccine period, Pfizer's stock price has declined by approximately 29% over the past five years, indicating market concerns regarding the company's future growth potential amid waning vaccine demand.
- Investor Caution: Analysts have noted that Pfizer did not make the current list of top stocks to buy, underscoring the need for investors to carefully assess the company's future return potential given its weaker drug pipeline.
See More
The Importance of Pfizer's Drug Pipeline Analysis
- Vaccine Sales Fluctuation: Pfizer's COVID-19 vaccine propelled revenue from $41.6 billion in 2020 to $81.2 billion in 2021, but sales plummeted to around $58 billion in 2023, highlighting the direct impact of changing vaccine demand on the company's financials.
- Declining Stock Trend: Although Pfizer's revenue remains higher than pre-pandemic levels, its stock price has dropped approximately 29% over the past five years, reflecting market concerns about future growth potential, especially amid waning vaccine demand.
- Acquisition Strategy: Pfizer's acquisition of Metsera, which has no market drugs but weight-loss candidates in trials, and Seagen in 2023 to enhance its oncology business, demonstrates the company's proactive efforts to identify new growth drivers.
- Importance of Drug Pipeline: Pfizer's situation underscores the critical importance of a robust drug pipeline, as failure to adapt when patents expire or drug demand declines can lead to significant shareholder losses, emphasizing the necessity for ongoing innovation and R&D.
See More
GLP-1 Medications Improve Patient Mood, Study Shows
- Mood Improvement Evidence: According to Dr. Angela Fitch, randomized controlled trials indicate that most patients experience mood improvements when treated with GLP-1 medications, suggesting potential psychological benefits of these drugs.
- Monitoring and Observations: At Knownwell, where Dr. Fitch oversees treatment for over 20,000 patients, she noted that they have not observed the emotional flatness described in media reports, indicating the safety and efficacy of GLP-1 treatments.
- Regulatory Developments: The lack of evidence supporting mental health risks has led regulators to remove suicidality warnings from GLP-1 medication labels, reflecting increased confidence in these drugs.
- Comprehensive Care Recommendations: Dr. Fitch advises that patients should receive comprehensive clinical care when obtaining GLP-1 prescriptions, emphasizing that psychological counseling and behavioral management are crucial for addressing mood shifts beyond medication alone.
See More
QSM Asset Management Initiates Position in Mobileye
- New Investment Position: According to an SEC filing dated April 15, 2026, QSM Asset Management initiated a new position in Mobileye Global Inc. by acquiring 611,003 shares during Q1 2026, with an estimated transaction value of $5.54 million, indicating confidence in the company's potential.
- Value Fluctuation: By the end of the quarter, the value of Mobileye's position was $4.13 million, reflecting price movements during the period and suggesting a cautious market sentiment regarding its future performance.
- Asset Allocation Insight: This new position constituted 2.02% of QSM's total reportable assets, highlighting the strategic diversification within the firm's investment portfolio, even as Mobileye's stock price has declined by 41.1% over the past year.
- Market Outlook Analysis: Despite facing significant market challenges, QSM's acquisition may signal an optimistic outlook for future profitability, particularly as autonomous driving technologies gain increasing importance in the automotive sector.
See More
QSM Asset Management Increases Stake in Mobileye
- Increased Holdings: QSM Asset Management acquired 611,003 shares of Mobileye in Q1 2026, with an estimated trade value of $5.54 million, reflecting confidence in the company's future prospects.
- Quarter-End Valuation: At quarter-end, the value of Mobileye's stake was $4.13 million, representing 2.02% of QSM's reportable assets under management, indicating its significance within the investment portfolio.
- Market Response: Despite Mobileye's stock being down over 80% from its all-time high, analysts project a forward P/E ratio of 30, suggesting the company is poised for profitability and rapid growth.
- Investment Timing: QSM's acquisition is viewed as a bullish signal in the current market climate, particularly as autonomous driving technology gains traction, potentially offering significant returns for investors.
See More
Trump Nominates New CDC Director Amid Turmoil
- Leadership Changes: Trump has nominated Erica Schwartz to serve as the CDC director, concluding a months-long search, with her confirmation pending Senate approval, which could significantly influence the agency's future direction.
- Interim Leadership Issues: Prior to Schwartz's nomination, Jay Bhattacharya served as acting director, but his term expired last month, highlighting instability within the CDC as the Vacancies Act limits interim officials to 210 days.
- Vaccine Policy Controversy: Amid leadership upheaval, declining morale, and significant staff turnover, the CDC faces major changes to U.S. vaccine policy, particularly after a judge blocked efforts to reduce the number of recommended childhood vaccinations, exacerbating public trust issues.
- Declining Public Trust: A February poll from KFF indicates a significant drop in public trust in federal health agencies during Kennedy's tenure as Secretary of Health and Human Services, which may hinder the CDC's effectiveness and implementation of future public health policies.
See More
The Importance of Pfizer's Drug Pipeline
- Vaccine Sales Fluctuation: Pfizer's COVID-19 vaccine revenue surged from $41.6 billion in 2020 to $81.2 billion in 2021, but sales plummeted to around $58 billion in 2023, highlighting the direct impact of changing vaccine demand on the company's financial health.
- Acquisition Strategy: Pfizer's acquisitions of Metsera, which focuses on weight-loss drug candidates in trials, and Seagen, aimed at bolstering its oncology business, reflect a strategic effort to fill future drug pipeline gaps and maintain market competitiveness.
- Stock Performance: Despite significant revenue growth during the COVID-19 vaccine period, Pfizer's stock price has declined by approximately 29% over the past five years, indicating market concerns regarding the company's future growth potential amid waning vaccine demand.
- Investor Caution: Analysts have noted that Pfizer did not make the current list of top stocks to buy, underscoring the need for investors to carefully assess the company's future return potential given its weaker drug pipeline.
See More
The Importance of Pfizer's Drug Pipeline Analysis
- Vaccine Sales Fluctuation: Pfizer's COVID-19 vaccine propelled revenue from $41.6 billion in 2020 to $81.2 billion in 2021, but sales plummeted to around $58 billion in 2023, highlighting the direct impact of changing vaccine demand on the company's financials.
- Declining Stock Trend: Although Pfizer's revenue remains higher than pre-pandemic levels, its stock price has dropped approximately 29% over the past five years, reflecting market concerns about future growth potential, especially amid waning vaccine demand.
- Acquisition Strategy: Pfizer's acquisition of Metsera, which has no market drugs but weight-loss candidates in trials, and Seagen in 2023 to enhance its oncology business, demonstrates the company's proactive efforts to identify new growth drivers.
- Importance of Drug Pipeline: Pfizer's situation underscores the critical importance of a robust drug pipeline, as failure to adapt when patents expire or drug demand declines can lead to significant shareholder losses, emphasizing the necessity for ongoing innovation and R&D.
See More
